checkAd
    Startseite > Aktien > Pulse Biosciences > Nachrichten
    Pulse Biosciences Aktie
    6,9000
     
    EUR
    +7,81 %
    +0,5000 EUR
    Letzter Kurs 10.05.24 Tradegate
    6,8500
     
    EUR
    587 STK
    Geldkurs 10.05.24
    7,0000
     
    EUR
    569 STK
    Briefkurs 10.05.24
    ISIN: US74587B1017 · WKN: A2AMY9 · SYM: 6L8 · USA

    Neueste Nachrichten

    Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
    09.05.24 · Business Wire (engl.) · Pulse Biosciences
    Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
    07.05.24 · Business Wire (engl.) · Pulse Biosciences
    Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
    02.05.24 · Business Wire (engl.) · Pulse Biosciences
    Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
    24.04.24 · Business Wire (engl.) · Pulse Biosciences
    Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
    28.03.24 · Business Wire (engl.) · Pulse Biosciences
    Pulse Biosciences Announces Plans to Initiate a Rights Offering
    28.03.24 · Business Wire (engl.) · Pulse Biosciences
    Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
    14.03.24 · Business Wire (engl.) · Pulse Biosciences
    Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX nsPFA Percutaneous Electrode System
    08.03.24 · Business Wire (engl.) · Pulse Biosciences
    Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX nsPFA 360° Cardiac Catheter First-in-Human Feasibility Study
    14.02.24 · Business Wire (engl.) · Pulse Biosciences
    Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
    31.01.24 · Business Wire (engl.) · Pulse Biosciences
    Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp
    02.01.24 · Business Wire (engl.) · Pulse Biosciences
    Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation (nsPFA) Cardiac Catheter
    20.12.23 · Business Wire (engl.) · Pulse Biosciences